Abstract: The current 2019–2021 marine pharmacology literature review provides a continuation of previous reviews covering the period 1998 to 2018. Preclinical marine pharmacology research during 2019–2021 was published by researchers in 42 countries and contributed novel mechanism-of-action pharmacology for 171 structurally characterized marine compounds. The peer-reviewed marine natural product pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral mechanism-of-action studies for 49 compounds, 87 compounds with antidiabetic and anti-inflammatory activities that also affected the immune and nervous system, while another group of 51 compounds demonstrated novel miscellaneous mechanisms of action, which upon further investigation, may contribute to several pharmacological classes. Thus, in 2019–2021, a very active preclinical marine natural product pharmacology pipeline provided novel mechanisms of action as well as new lead chemistry for the clinical marine pharmaceutical pipeline targeting the therapy of several disease categories.

中文翻译：

---

2019-2021年海洋药理学：具有抗菌、抗糖尿病、抗真菌、抗炎、抗原虫、抗结核和抗病毒活性的海洋化合物；影响免疫和神经系统以及其他其他作用机制


摘要：当前的2019-2021年海洋药理学文献综述是对1998年至2018年期间先前综述的延续。2019-2021年期间的临床前海洋药理学研究由42个国家的研究人员发表，并为171个国家贡献了新的作用机制药理学。具有结构特征的海洋化合物。同行评审的海洋天然产物药理学文献报道了 49 种化合物的抗菌、抗真菌、抗原虫、抗结核和抗病毒作用机制研究，其中 87 种化合物具有抗糖尿病和抗炎活性，同时也影响免疫和神经系统，而另一51 种化合物显示出新颖的多种作用机制，经过进一步研究，可能有助于多种药理学类别。因此，在2019-2021年，非常活跃的临床前海洋天然产物药理学管道为针对多种疾病类别治疗的临床海洋药物管道提供了新颖的作用机制以及新的先导化学。